Nyrada (ASX:NYR) said a phase one clinical trial safety review committee raised no issues after reviewing cumulative safety and pharmacokinetic data from the first and second cohorts in its clinical trial for the NYR-BI03 drug candidate, enabling the clinical trial to proceed to the third cohort, according to a Friday Australian bourse filing.
NYR-BI03 is a small-molecule drug candidate for neuroprotection and cardioprotection indications.
The trial is seeking to study the safety and tolerability of NYR-BI03 in healthy volunteers, as well as to determine the blood pharmacokinetics of an intravenous dose of NYR-BI03 when administered as a three-hour infusion.
Its shares rose 5% in recent trading on Friday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.